Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Lirentelimab

Catalog No. T76869Cas No. 2283348-97-8
Alias Antolimab, Anti-Siglec-8 Reference Antibody, AK002, AK 002

Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.

Lirentelimab

Lirentelimab

Catalog No. T76869Alias Antolimab, Anti-Siglec-8 Reference Antibody, AK002, AK 002Cas No. 2283348-97-8
Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.
Pack SizePriceAvailabilityQuantity
1 mg$197In Stock
5 mg$516In Stock
10 mg$828In Stock
25 mg$1,230In Stock
50 mg$1,650In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:6.78 mg/mL
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.
Targets&IC50
SIGLEC8:464 pM (affinity)
In vitro
The antigen-binding fragment of Lirentelimab binds with an affinity of 464 pM to the extracellular structural domain of recombinant SIGLEC8. Lirentelimab exhibits a high affinity for in vitro-expressed SIGLEC8 as well as SIGLEC8 expressed on eosinophils and via the Fc region on NK cells. At a concentration of 1 µg/mL, Lirentelimab selectively binds to eosinophils in human peripheral blood as well as eosinophils and mast cells in human lung tissue. In addition, Lirentelimab induced apoptosis in IL-5-activated eosinophils when acted at concentrations ranging from 0.0001 to 100 μg/mL for 30 minutes. In peripheral blood leukocyte samples from healthy donors, Lirentelimab had a half-maximal effect concentration of 1.9 ng/mL on eosinophils and elicited an antibody-dependent cytotoxic response.Lirentelimab also reduced the number of eosinophils in isolated human tissues. [1]
In vivo
Lirentelimab significantly inhibited IgE-mediated mast cell activation after a single intravenous injection at a dose of 100 μg in a mouse model of systemic allergic reaction. [1]
AliasAntolimab, Anti-Siglec-8 Reference Antibody, AK002, AK 002
Chemical Properties
Cas No.2283348-97-8
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Lirentelimab | purchase Lirentelimab | Lirentelimab cost | order Lirentelimab | Lirentelimab in vivo | Lirentelimab in vitro